Company intelligence / Profile preview

ApoPharma Inc.

Toronto, Ontario, Canadaorpha.net ↗

Ownership: Private
Employees: ~218
Development stage: Commercial

Overview

ApoPharma has developed Ferriprox (deferiprone), an iron chelator approved in over 60 countries including the USA for treating iron overload in thalassemia patients. The company is also conducting research on iron-related pathology in neurodegeneration and immune system disorders.

Therapeutic areas: DermatologyHematologyNeurology
Modalities: Small moleculesIron chelatorsOligopeptides
Industry: Biotech

Drug pipeline

3 assets

deferiprone

Commercial

Indications: Anemia, Sickle cell disease, Systemic iron overload, Thalassemia syndromes

2 more assets in the full pipeline.

Request access →

Partnerships

TIRCON ProjectDEEP Project

Beyond the preview

Go deeper on ApoPharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ApoPharma Inc..

Explore the full profile